Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7186 to 7200 of 7675 results

  1. Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (TA172)

    This guidance has been updated and replaced by NICE technology appraisal guidance 473.

    Technology appraisal guidance
    Published
    24 June 2009

  2. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205)

    This guidance has been updated and replaced by NICE technology appraisal guidance 293.

    Technology appraisal guidance
    Published
    27 October 2010

  3. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

    Technology appraisal guidance
    Published
    27 March 2001

  4. Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)

    This guidance has been replaced by NICE technology appraisal guidance 474.

    Technology appraisal guidance
    Published
    26 May 2010

  5. Erlotinib for the treatment of non-small-cell lung cancer (TA162)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Technology appraisal guidance
    Last updated
    1 December 2012

  6. Febuxostat for the management of hyperuricaemia in people with gout (TA164)

    This guidance has been updated and replaced by NICE guideline NG219.

    Technology appraisal guidance
    Published
    17 December 2008

  7. Cochlear implants for children and adults with severe to profound deafness (TA166)

    This guidance has been updated and replaced by NICE technology appraisal guidance 566.

    Technology appraisal guidance
    Published
    28 January 2009

  8. Endovascular stent–grafts for the treatment of abdominal aortic aneurysms (TA167)

    This guidance has been updated and replaced by NICE guideline NG156.

    Technology appraisal guidance
    Published
    25 February 2009

  9. Autologous cartilage transplantation for full thickness cartilage defects in knee joints (TA16)

    This guidance has been replaced by NICE technology appraisal guidance 89 [Replaced by NICE technology appraisal guidance 477].

    Technology appraisal guidance
    Published
    16 December 2000

  10. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (TA132)

    This guidance has been updated and replaced by NICE technology appraisal guidance 385.

    Technology appraisal guidance
    Published
    28 November 2007

  11. Omalizumab for severe persistent allergic asthma (TA133)

    This guidance has been replaced by NICE technology appraisal guidance 278.

    Technology appraisal guidance
    Published
    28 November 2007

  12. Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA12)

    This guidance has been replaced by NICE technology appraisal guidance 47. 

    Technology appraisal guidance
    Published
    26 September 2000

  13. Cardiac resynchronisation therapy for the treatment of heart failure (TA120)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Technology appraisal guidance
    Published
    23 May 2007

  14. Alteplase for the treatment of acute ischaemic stroke (TA122)

    This guidance has been updated and replaced by NICE technology appraisal guidance 264 issued in September 2012.

    Technology appraisal guidance
    Published
    27 June 2007

  15. Adalimumab for the treatment of psoriatic arthritis (TA125)

    This guidance has been updated and replaced by NICE technology appraisal guidance 199.

    Technology appraisal guidance
    Published
    22 August 2007